tirzepatide glp-1 gip Compounded GLP-1/GIP (3 Month) – Verge Lose up to 20% of your body weight with this simple Molecular structure of tirzepatide and

SURMOUNT-5, the most anticipated trial, will compare tirzepatide to a GLP-1 agonist approved for the treatment of obesity in obese or overweight patients ( without type 2 diabetes) with weight-related co-morbidities

It activates two different receptors in the body: GIP (glucose-dependent insulinotropic polypeptide) GLP-1 (glucagon-like peptide-1) By stimulating both, tirzepatide helps: Reduce appetite Increase feelings of fullness Improve insulin sensitivity Lower blood sugar These combined effects help many people eat less and lose more weight over time

Months 4 to 6 and beyond: Real density change in responders

Clinical studies have shown that patients using tirzepatide often lose a greater percentage of body weight compared to those on placebo or other therapies

You have tried willpower, and willpower failed

Data availability for some endpoints (e.g